Foundation / Corporation
Israel Cancer Research Fund (ICRF)
01/17/18 11:59 PM ET Receipt
Grants providing a stipend of $83,333 per year to Israel established investigators for research to enhance quality of life for medical patients with life-threatening and serious diseases, such as cancer. Funding will be awarded to Israeli institutions or collaborating institutions and must be used for specific research under the direction of a designated principal investigator studying the treatment of pain, side effects, and emotional problems experienced by cancer patients in order to maintain the best possible quality of life. Emphasis is placed on non-opioid solutions.
Quality of Life care is care given to improve the life of patients who have a serious or life-threatening disease, such as cancer. The goal of Quality of Life care is to prevent or treat, as early as possible, the symptoms and side effects of the disease and its treatment, in addition to the related psychological, social, and spiritual problems. Quality of Life care is given throughout a patient’s experience with cancer. It should begin at diagnosis and continue through treatment, follow-up care, and the end of life. However, most treatment regimens focus on opioid medications, which are effective, but have problematic side effects.
Often, quality of life care specialists work as part of a multidisciplinary team to coordinate care. While not a requirement, grants that utilize interdisciplinary approaches and that are multi-investigator are encouraged. International Collaboration is acceptable. However, the principal investigator must be located in Israel, while the collaborating investigator(s) may be located in, and citizens of, North America. The support to the participating institutions will be divided such that 80% of the funds will be designated for the Israeli investigator(s) and institution, and 20% for the investigator(s) in North America. For the North American partners, it would be prudent to ensure that their institutions will accept ICRF grant funds with no indirect costs appended or at most with indirect costs at 10%.
For purposes of this grant category only, funds may be requested for basic, clinical or translational research, which must relate to quality of life issues for cancer patients (with an emphasis on non- opioid solutions) and must be conducted, in whole or in part, in Israel.
GrantWatch ID#: 182708
It is anticipated that up to four grants will be awarded.
Awarded grants may provide a total stipend of $250,000 (approximately $83,333 per year).
Awarded grants will be for a period of three (3) years.
Funding for the second and third years will be contingent upon acceptable progress during years one and two of the grant, as evidenced in a short report due annually.
Awards are activated September 1, 2018.
ICRF Quality of Life Grants are intended to support the research of established investigators. The application must originate from an Israeli scientist/institution, who will be designated as the principal investigator. All additional collaborating investigators/institutions, whether in Israel or in North America, will be considered as co-investigators.
The Israeli institutions are not permitted to utilize ICRF funds for overhead or other indirect costs. While the ICRF would prefer that the North American institutions do the same, only allow a maximum of 10% for indirect costs is allowed.
Funds for cancer research are available to citizens of Israel, both native-born and those who have settled. Funds are not available to visiting scientists. (Proof of Israeli citizenship must be furnished upon request.)
The application deadline is January 17, 2018, at 11:59 PM ET.
-Application Received by the Fund in New York: January 17, 2018
-Notification of Decision: July 1, 2018
-Activation of Award: September 1, 2018
Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.
Register to apply:
Ellen T. Rubin, Director, Research Grants
Israel Cancer Research Fund
52 Vanderbilt Avenue, Suite 1510
New York, NY 10017-3834